Clinical Trial

Expanding Genetic Access for Prostate Cancer Survivors

Study acronym: ENGAGE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing. Evaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). Explore the ways (methods) that influence how participants experience the intervention. The main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.
Trial Details
NCT Number NCT07618520
Lead Sponsor Georgetown University
Collaborators: National Cancer Institute (NCI), Rutgers University
Conditions Prostate Cancer Patients, Hereditary Cancer, Genetic Testing
Enrollment 500 participants
Start Date 2026-08-01
Primary Completion 2029-07-30 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01